Skip to content

Erythropoietin effect on ischemic_reperfusion injury

Erythropoietin effect on ischemic_reperfusion injury in cronary artery bypass graft surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016011621087N1
Enrollment
90
Registered
2016-01-16
Start date
2016-01-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic reperfusion injury in chronic artery bypass graft surgery. Chronic ischaemic heart disease

Interventions

Intervention 1: Infusion of 50cc normal saline as placebo in control group, during aortic clamping(45-60 minutes). Intervention 2: Infusion of 60000 IU erythropoietin in intervention group,during aort
Treatment - Drugs
Infusion of 50cc normal saline as placebo in control group, during aortic clamping(45-60 minutes)
Infusion of 60000 IU erythropoietin in intervention group,during aortic clamping (45-60 minutes)

Sponsors

Pooyesh Darou company and Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: The inclusion criterion are revascularization requirement according to angiographic evidence,cronary artery bypass graft (CABG) surgery in elective situation, for the first time and with cardiopulmonary bypass(CPB). The exclusion criteria are comprised of history of myocardial infarction in the past 3 months, previous myocardial trauma or major surgery in the past 3 months, Cr>2, receiving streptokinase or previous reperfusion treatments, EPO intake in the recent 6 months, known thrombo-embolic disorder, malignant disease,uncontrolled hypertension and polycythemia

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Interleukin 6. Timepoint: before operation (base),just after operation,24 hours after operation,48 hours after operation. Method of measurement: elisa.;YKL-40. Timepoint: before operation (base),just after operation,24 hours after operation,48 hours after operation. Method of measurement: elisa.;TNF-a. Timepoint: before operation (base),just after operation,24 hours after operation,48 hours after operation. Method of measurement: elisa.;Added at 2016-09-22: B type natriuretic peptide(BNP. Timepoint: before operation (base),just after operation,24 hours after operation,48 hours after operation. Method of measurement: Added at 2016-09-22: ELISA.

Secondary

MeasureTime frame
CPK-MB. Timepoint: befor operation(base),6 hour after operation,12 hour after operation. Method of measurement: elisa.;Bleeding. Timepoint: during operation,6 hour after operation,12 hour after operation,24 hour after operation. Method of measurement: volume of bleeeding.;Troponin. Timepoint: befor operation(base),6 hour after operation,12 hour after operation. Method of measurement: elisa.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactdr foroughi

heart surgery department ofShahid Modarres hospital

mahnoosh.foroughi@gmail.com+98 917 161 3954

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026